You must be a member and be signed in to view this page. Please click here to login if you are already a member.
strategies to deal with the lack of development into agents targeting microbial infections was held. The current business model for drug development does not work with antimicrobials and consequently almost all large pharma are no long involved in drug development in this space.
The meeting was to discuss different options with various players and the slides are available below.
Download
You must be a member and be signed in to view this page. Please click here to login if you are already a member.
You must be a member and be signed in to view this page. Please click here to login if you are already a member.
You must be a member and be signed in to view this page. Please click here to login if you are already a member.